Dianthus Therapeutics (DNTH) Receivables - Net (2022 - 2025)
Dianthus Therapeutics has reported Receivables - Net over the past 4 years, most recently at $5.0 million for Q3 2025.
- Quarterly results put Receivables - Net at $5.0 million for Q3 2025, up 259.71% from a year ago — trailing twelve months through Sep 2025 was $5.0 million (up 259.71% YoY), and the annual figure for FY2023 was $294000.0, down 93.74%.
- Receivables - Net for Q3 2025 was $5.0 million at Dianthus Therapeutics, up from $39000.0 in the prior quarter.
- Over the last five years, Receivables - Net for DNTH hit a ceiling of $5.0 million in Q3 2025 and a floor of $39000.0 in Q2 2025.
- Median Receivables - Net over the past 4 years was $840000.0 (2024), compared with a mean of $1.5 million.
- Biggest five-year swings in Receivables - Net: skyrocketed 499.14% in 2024 and later crashed 95.36% in 2025.
- Dianthus Therapeutics' Receivables - Net stood at $4.7 million in 2022, then crashed by 93.74% to $294000.0 in 2023, then surged by 372.79% to $1.4 million in 2024, then soared by 259.71% to $5.0 million in 2025.
- The last three reported values for Receivables - Net were $5.0 million (Q3 2025), $39000.0 (Q2 2025), and $1.0 million (Q1 2025) per Business Quant data.